Inverse agonism : proceedings of the Esteve Foundation Symposium X, S'Agaró (Girona), Spain, 2-5 October 2002
著者
書誌事項
Inverse agonism : proceedings of the Esteve Foundation Symposium X, S'Agaró (Girona), Spain, 2-5 October 2002
(International congress series, No. 1249)(Esteve Foundation symposia, vol. 10)
Elsevier, 2003
大学図書館所蔵 全4件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
内容説明・目次
内容説明
This volume reflects the current state of thinking and debates with regard to inverse agonism. It constitutes the first book published on this issue and holds the contributions and recorded discussions of the 10th Esteve Foundation Symposium held in 2002. Inverse agonism at G-protein-coupled receptors is a novel pharmacological concept with important consequences for the understanding of receptor mechanisms and drug action. Since its first description in 1989 the concept of inverse agonism has dramatically changed the view on current and future medicines. Next to traditional agonists and antagonists the drug repertoire has been expanded now with a novel category of ligands, i.e. 'inverse agonists'.
目次
About the Esteve Foundation. Introduction. Different mechanisms of negative efficacy. Distinguishing inverse agonists from negative antagonists (T. Costa et al.). Novel approaches to enhance the detection of receptor constitutive activity and inverse agonists (G. Milligan). From inverse agonism to "Paradoxical Pharmacology" (R.A. Bond, K.L.J. Evans, Z. Callaerts-Vegh). Different inverse agonist activities of beta-adrenergic receptor antagonists - pharmacological characterization and therapeutical implications in the treatment of chronic heart failure (C. Maack, M. Bohm (Germany). Inverse agonism at beta1 -adrenergic receptors (M.J. Lohse, C. Hoffmann, S. Engelhardt). Physiological and pathological role of the constitutively active alpha1D-adrenoceptors (P. D'Ocon). Inverse agonism at cannabinoid receptors (R.G. Pertwee). Inverse agonism at adenosine A1 receptors (R.A.F. de Ligt, A. Lorenzen, A.P. IJzerman). Differential ligand efficacy at h5 HT1A receptor-coupled G-protein subtypes: a commentary (A. Newman-Tancredi). 5-HT2c constitutive receptor activity: effector pathway-dependence (K.A. Berg, W.P. Clarke). Modulation of constitutive GPCR activity: a way of life? (R. Leurs et al.). Constitutive activity of the recombinant and native histamine H3 receptor (J.M. Arrang et al.). Inverse agonism of the antipsychotic drugs at the D2 dopamine receptor (P.G. Strange). Inverse agonism at dopamine D2 receptors: a receptor recalcitrant to high levels of constitutive activation (T. Wurch, E.A. Boutet-Robinet, P.J. Pauwels). Platelet-activating factor receptor: differential regulation and signaling by agonists and inverse agonists (D.J. Dupre, M Rola-Pleszczynski, J. Stankova). AgRP, physiological role of an inverse agonist (R.A.H. Adan, W.A.J. Nijenhuis, M.J.H. Kas). Inverse agonism at neurotensin receptors NTS1 and NTS2 (P. Kitabgi). The thyrotropin receptor, a GPCR with a built in inverse agonist (G. Vassart). Inverse agonism and the PTH/PTHrP receptor (R. Gensure, P.H. Carter, T.J. Gardella). Inverse agonists to explore the mechanisms of metabotropic glutamate receptor activity (L. Prezeau et al.). Control of constitutive activity of metabotropic glutamate receptors by Homer proteins (L. Fagni et al.). General discussion. Author index.
「Nielsen BookData」 より